Comparison of early and late start of antihypertensive agents and baroreceptor reflexes

K Kumagai1, H Suzuki, M Ichikawa

  • 1Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.

Insights

Starting antihypertensive treatment early in spontaneously hypertensive rats significantly improves baroreceptor reflex function. Early intervention is crucial for preserving end-organ function in hypertension management.

Area of Science:

  • Cardiovascular Physiology
  • Pharmacology
  • Hypertension Research

Background:

  • Baroreceptor reflex function is vital for maintaining end-organ function in hypertensive patients.
  • Hypertension can impair baroreceptor reflex sensitivity, affecting blood pressure regulation.

Purpose of the Study:

  • To investigate the impact of early versus late initiation of antihypertensive treatment on baroreceptor reflex function.
  • To compare the effects of trichlormethiazide, atenolol, nicardipine, and enalapril on baroreceptor reflex gain.

Main Methods:

  • Spontaneously hypertensive rats (SHR) were divided into early-start (10–36 weeks) and late-start (28–36 weeks) treatment groups.
  • Antihypertensive agents were administered, and baroreceptor reflex gain for renal sympathetic nerve activity and heart rate was evaluated using ramp infusions.
  • Measurements were compared to untreated SHR at various ages (10, 28, 36 weeks).

Main Results:

  • In untreated SHR, heart rate gain decreased with age, while renal sympathetic nerve activity gain remained unchanged.
  • Early-start treatment with nicardipine and enalapril significantly improved renal sympathetic nerve activity gain.
  • Early-start treatment with atenolol and enalapril markedly improved heart rate gain, with nicardipine showing slight improvement in late-start groups.

Conclusions:

  • Early initiation of antihypertensive therapy significantly enhances baroreceptor reflex function compared to late initiation.
  • A critical, age-sensitive phase for intervention exists during hypertension development.
  • Early antihypertensive treatment is recommended in clinical practice to preserve baroreceptor reflex integrity.

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Neural Regulation of Blood Pressure01:18

Neural Regulation of Blood Pressure

The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...